BALTIMORE--(BUSINESS WIRE)--Dec. 21, 2005--Osiris Therapeutics, Inc. announced that it has closed a $19 million private equity round. The money will fund the company’s five ongoing clinical trial programs using their proprietary adult stem cell technology platform. The round was arranged by Swiss investment firm Friedli Corporate Finance, Inc. In total, the company has raised $70 million in 2005.
